Gainers
- Biodesix (NASDAQ:BDSX) shares rose 77.3% to $9.68 during Monday's regular session. The market value of their outstanding shares is at $43.6 million.
- Beam Therapeutics (NASDAQ:BEAM) stock moved upwards by 28.12% to $35.3. The market value of their outstanding shares is at $2.7 billion.
- Cellectar Biosciences (NASDAQ:CLRB) shares moved upwards by 27.11% to $3.92. The company's market cap stands at $13.0 million.
- Iridex (NASDAQ:IRIX) shares moved upwards by 23.47% to $1.42. The company's market cap stands at $19.7 million.
- Outset Medical (NASDAQ:OM) shares moved upwards by 23.02% to $5.61. The company's market cap stands at $82.7 million.
- Day One Biopharmaceutical (NASDAQ:DAWN) stock rose 22.48% to $10.95. The company's market cap stands at $917.9 million.
Losers
- Atara Biotherapeutics (NASDAQ:ATRA) shares fell 52.9% to $6.44 during Monday's regular session. The company's market cap stands at $98.5 million.
- Lyra Therapeutics (NASDAQ:LYRA) stock fell 46.91% to $2.0. The company's market cap stands at $6.6 million.
- NovaBay Pharmaceuticals (AMEX:NBY) stock fell 33.23% to $12.79. The company's market cap stands at $2.4 billion.
- Lexeo Therapeutics (NASDAQ:LXEO) stock decreased by 28.04% to $7.58. The company's market cap stands at $769.2 million.
- Shuttle Pharmaceuticals (NASDAQ:SHPH) stock fell 22.45% to $1.5. The company's market cap stands at $3.0 million.
- Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock decreased by 20.27% to $0.12. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BDSXBiodesix Inc
$7.70-4.70%
BEAMBeam Therapeutics Inc
$33.850.47%
CLRBCellectar Biosciences Inc
$3.80-%
DAWNDay One Biopharmaceuticals Inc
$11.18-1.32%
IRIXIRIDEX Corp
$1.501.35%
LXEOLexeo Therapeutics Inc
$8.11-0.12%
LYRALyra Therapeutics Inc
$2.03-1.46%
NBYNovaBay Pharmaceuticals Inc
$12.82-4.68%
OMOutset Medical Inc
$5.52-0.90%
SHPHShuttle Pharmaceuticals Holdings Inc
$1.451.40%
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

